Private Practice

Jun 29, 2025

F90 Attention-Deficit/Hyperactivity Disorder (ADHD): Comprehensive Guide for Mental Health Professionals

Brayden Efseroff, MD

Understand ADHD: A comprehensive guide for mental health professionals on ICD-10 code F90, covering diagnosis, symptoms, treatment, and patient resources for Attention-Deficit/Hyperactivity Disorder.

Table of Contents

    Want to see it yourself?

    Quick Reference

    Code: F90 (with 4th character specifications)
    Disorder: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Category: Neurodevelopmental Disorders
    Billing Status: Active code for reimbursement (requires 4th character)
    DSM-5 Equivalent: 314.0x (Attention-Deficit/Hyperactivity Disorder)
    Common Comorbidities: Learning Disorders, Oppositional Defiant Disorder, Conduct Disorder, Anxiety Disorders, Depression, Autism Spectrum Disorder

    Clinical Description

    Attention-Deficit/Hyperactivity Disorder is a neurodevelopmental disorder characterized by persistent patterns of inattention and/or hyperactivity-impulsivity that interfere with functioning or development. Symptoms must be present before age 12, occur in multiple settings, and cause clinically significant impairment.

    ICD-10 Coding Specifications

    F90.0 - Attention-deficit hyperactivity disorder, predominantly inattentive type
    F90.1 - Attention-deficit hyperactivity disorder, predominantly hyperactive type
    F90.2 - Attention-deficit hyperactivity disorder, combined type
    F90.8 - Attention-deficit hyperactivity disorder, other type
    F90.9 - Attention-deficit hyperactivity disorder, unspecified type

    Diagnostic Criteria

    Inattention Symptoms (6+ required for children, 5+ for adolescents/adults):

    • Often fails to give close attention to details or makes careless mistakes

    • Often has difficulty sustaining attention in tasks or play activities

    • Often does not seem to listen when spoken to directly

    • Often does not follow through on instructions and fails to finish tasks

    • Often has difficulty organizing tasks and activities

    • Often avoids, dislikes, or is reluctant to engage in tasks requiring sustained mental effort

    • Often loses things necessary for tasks or activities

    • Is often easily distracted by extraneous stimuli

    • Is often forgetful in daily activities

    Hyperactivity-Impulsivity Symptoms (6+ required for children, 5+ for adolescents/adults):

    Hyperactivity:

    • Often fidgets with or taps hands or feet or squirms in seat

    • Often leaves seat in situations when remaining seated is expected

    • Often runs about or climbs in situations where it is inappropriate

    • Often unable to play or engage in leisure activities quietly

    • Is often "on the go," acting as if "driven by a motor"

    • Often talks excessively

    Impulsivity:

    • Often blurts out answers before questions have been completed

    • Often has difficulty waiting their turn

    • Often interrupts or intrudes on others

    Additional Criteria:

    • Several symptoms present before age 12 (but not necessarily impairing)

    • Symptoms present in 2+ settings (home, school, work)

    • Clear evidence of clinically significant impairment

    • Symptoms not better explained by another mental disorder

    Presentation Types

    Type

    Criteria

    Clinical Features

    Predominantly Inattentive (F90.0)

    6+ inattention symptoms, <6 hyperactivity-impulsivity symptoms

    Difficulty focusing, disorganization, forgetfulness

    Predominantly Hyperactive-Impulsive (F90.1)

    6+ hyperactivity-impulsivity symptoms, <6 inattention symptoms

    Restlessness, impulsivity, difficulty sitting still

    Combined Type (F90.2)

    6+ symptoms from both categories

    Most common presentation, mixed symptoms

    Differential Diagnosis

    Condition

    Distinguishing Features

    ICD-10 Code

    Autism Spectrum Disorder

    Restricted interests, repetitive behaviors, social communication deficits

    F84.0

    Intellectual Disability

    Significantly below-average intellectual functioning

    F70-F79

    Specific Learning Disorder

    Academic difficulties in specific domains without generalized attention problems

    F81.x

    Oppositional Defiant Disorder

    Defiant, hostile behavior toward authority figures

    F91.3

    Conduct Disorder

    Violation of basic rights of others or social norms

    F91.x

    Anxiety Disorders

    Anxiety-driven inattention and restlessness

    F40-F41

    Bipolar Disorder

    Episodic mood disturbances with periods of normalcy

    F31.x

    Substance Use Disorders

    Symptoms related to substance intoxication/withdrawal

    F10-F19

    Transdiagnostic Considerations

    ADHD is part of the neurodevelopmental disorder spectrum and frequently co-occurs with other conditions. Several neuropsychological constructs are involved. In particular, executive functioning deficits are central to ADHD and impact multiple life domains. Treatment often requires addressing comorbid conditions and environmental factors.

    Assessment Tools

    Validated Screening & Assessment Instruments

    Instrument

    Description

    Age Range

    Scoring

    Adult ADHD Self-Report Scale (ASRS-v1.1)

    WHO-developed screening for adult ADHD

    18+ years

    Score cutoffs for likelihood of ADHD

    Conners Rating Scales (CRS-4)

    Comprehensive ADHD assessment with parent, teacher, and self-report forms

    6-18 years

    T-scores: <60: Average

    60-64: Slightly Elevated

    65-69: Elevated

    ≥70: Very Elevated

    Vanderbilt Assessment Scales

    Brief screening tool for ADHD and comorbidities

    6-12 years

    Symptom count and impairment ratings

    Strengths and Weaknesses of ADHD Symptoms and Normal Behavior Scale (SWAN)

    Bidirectional (strengths and weaknesses) DSM-based screening and monitoring tool with parent, caregiver, and teacher forms 

    5-18 years

    Comparison to population with  metrics of internal consistency

    Behavior Assessment System for Children (BASC-3)

    Comprehensive behavioral assessment

    2-21 years

    T-scores with clinical significance levels

    QbTest

    Objective measures of sustained attention, hyperactivity, and impulsivity administered through digital platform

    6+ years

    Various indices of attention and response control

    Treatment Approaches

    Evidence-Based Psychosocial Interventions

    Behavioral interventions are the foundation of ADHD treatment, particularly for children. The combination of medication and behavioral therapy typically provides optimal outcomes.

    Approach

    Level of Evidence

    Key Components

    Age Group

    Behavioral Parent Training

    Strong

    Contingency management, positive reinforcement, consistent consequences

    Children/Adolescents

    Behavioral Classroom Management

    Strong

    Token economies, daily report cards, environmental modifications

    School-age

    Cognitive Behavioral Therapy

    Moderate

    Problem-solving skills, self-monitoring, cognitive restructuring

    Adolescents/Adults

    Social Skills Training

    Moderate

    Peer interaction skills, communication training, group activities

    Children/Adolescents

    Executive Function Training

    Emerging

    Working memory training, organization skills, planning strategies

    All ages

    Mindfulness-Based Interventions

    Emerging

    Attention training, emotional regulation, present-moment awareness

    Adolescents/Adults

    Evidence-Based Medication Options

    These tables include only a sample of available formulations. Please provide recommendations according to your patient’s specific clinical factors.

    Stimulant medications are first-line treatment for ADHD, with non-stimulants as alternatives for those who cannot tolerate or do not respond to stimulants.

    Stimulant Medications

    Medication

    Duration

    Starting Dose

    Target Dose

    Notes

    Methylphenidate-Based

    Ritalin (immediate-release)

    3-4 hours

    5 mg BID

    10-20 mg BID-TID

    Multiple daily doses required

    Ritalin LA

    8 hours

    10-20 mg daily

    20-60 mg daily

    Once daily dosing

    Concerta

    12 hours

    18-36 mg daily

    36-72 mg daily

    OROS delivery system

    Daytrana (patch)

    9 hours

    10 mg patch

    15-30 mg patch

    Transdermal option

    Amphetamine-Based

    Adderall (immediate-release)

    4-6 hours

    5 mg BID

    10-20 mg BID

    Mixed amphetamine salts

    Adderall XR

    10-12 hours

    10-20 mg daily

    20-60 mg daily

    Extended-release capsule

    Vyvanse

    12-14 hours

    20-30 mg daily

    50-70 mg daily

    Prodrug, abuse-deterrent

    Non-Stimulant Medications

    Medication

    Mechanism

    Starting Dose

    Target Dose

    Notes

    Atomoxetine (Strattera)

    NRI

    0.5 mg/kg/day

    1.2-1.8 mg/kg/day

    24-hour coverage, no abuse potential

    Guanfacine XR (Intuniv)

    Alpha-2A agonist

    1 mg daily

    1-4 mg daily

    Helpful for hyperactivity, sleep issues

    Clonidine XR (Kapvay)

    Alpha-2 agonist

    0.1 mg daily

    0.1-0.4 mg daily

    Sedating, helpful for aggression

    Viloxazine (Qelbree)

    NRI

    Age/weight based

    Age/weight based

    Newer option, once daily

    Medication Management Considerations

    Monitoring Parameters:

    • Height and weight (growth charts)

    • Blood pressure and heart rate

    • Sleep patterns and appetite

    • Mood and behavioral changes

    • Academic/occupational functioning

    • Side effect assessment

    Common Side Effects:

    • Appetite suppression and weight loss

    • Sleep difficulties

    • Mood changes (irritability, sadness)

    • Growth suppression (temporary)

    • Cardiovascular effects (mild)

    • Rebound symptoms

    Multimodal Treatment Approach

    Children (6-11 years):

    • Behavioral parent training (first-line)

    • Behavioral classroom interventions

    • Medication if behavioral interventions are insufficient

    • School accommodations and supports

    Adolescents (12-17 years):

    • Combination of medication and behavioral therapy

    • Academic accommodations and support

    • Driver education and safety planning

    • Transition planning for adulthood

    Adults (18+ years):

    • Medication management

    • CBT focused on organization and time management

    • Workplace accommodations

    • Treatment of comorbid conditions

    Addressing Common Treatment Challenges

    Challenge

    Strategies

    Medication adherence

    Long-acting formulations, reminder systems, address stigma

    Academic underachievement

    IEP/504 plans, tutoring, study skills training

    Social difficulties

    Social skills training, peer support groups

    Emotional dysregulation

    DBT skills, mindfulness, emotion regulation strategies

    Substance use risk

    Psychoeducation, monitoring, non-stimulant options

    Driving safety

    Graduated licensing, medication timing, safety education

    Educational and Workplace Considerations

    School-Based Interventions

    Section 504 Accommodations:

    • Extended time on tests and assignments

    • Preferential seating (front of class, away from distractions)

    • Break tasks into smaller segments

    • Use of assistive technology

    • Modified homework assignments

    • Alternative testing formats

    Individualized Education Program (IEP):

    • May qualify under "Other Health Impairment" category

    • Requires documented adverse impact on educational performance

    • Includes specialized instruction and related services

    • Annual goals and progress monitoring

    Classroom Strategies:

    • Clear, consistent routines and expectations

    • Visual schedules and reminders

    • Frequent feedback and reinforcement

    • Movement breaks and fidget tools

    • Minimize distractions in environment

    Workplace Accommodations

    Common ADA Accommodations:

    • Flexible scheduling and break times

    • Quiet workspace or noise-canceling headphones

    • Written instructions and task lists

    • Extended deadlines for projects

    • Technology aids (reminder apps, organizers)

    • Regular check-ins with supervisor

    Documentation, Coding, and Reimbursement

    ICD-10 Coding Tips

    • F90 requires a 4th character to specify presentation type

    • Document specific symptoms from both inattention and hyperactivity-impulsivity criteria

    • Include age of onset (must be before age 12)

    • Specify settings where impairment occurs

    • Document functional impairment in academic, social, or occupational domains

    • Consider coding comorbid conditions separately

    Medical Necessity Documentation Language

    Example statements to support medical necessity:

    • "Patient exhibits [X] symptoms of inattention and [X] symptoms of hyperactivity-impulsivity present since age [X]"

    • "ADHD symptoms cause significant impairment in academic performance as evidenced by [specific examples]"

    • "Functional impairment documented across multiple settings including home and school/work"

    • "Previous interventions attempted include [list] with limited success"

    • "Current [rating scale] scores indicate [severity level] ADHD symptoms requiring treatment"

    Other Documentation Requirements for Reimbursement

    • Comprehensive developmental history

    • Multi-informant assessment (parent, teacher, self-report)

    • Evidence of symptoms before age 12

    • Documentation of impairment in 2+ settings

    • Differential diagnosis ruling out other conditions

    • Treatment plan with specific, measurable goals

    • Regular monitoring and adjustment documentation

    Specific Payer Considerations

    Payer

    Typical Reimbursement

    Authorization Requirements

    Special Considerations

    Medicare

    Limited coverage for adults

    Prior auth may be required

    Focus on functional impairment

    Medicaid

    Generally covered

    Varies by state

    May require specific provider types

    Private Insurance

    Usually covered

    May require prior auth for medications

    Step therapy requirements common

    School Districts

    Assessment and services under IDEA/504

    Referral process required

    Free appropriate public education

    Patient Education Resources

    Handouts for Patients and Families

    Digital Resources

    Recommended Apps:

    • Forest: Focus and productivity timer

    • Todoist: Task management and organization

    • Brain Focus: Pomodoro technique timer

    • Habitica: Gamified habit tracking

    • Freedom: Website and app blocker

    Online Communities:

    Psychoeducational Talking Points

    • ADHD as a neurodevelopmental difference: ADHD involves differences in brain structure and function, particularly in areas responsible for executive functioning, attention regulation, and impulse control. Neuroimaging studies show differences in the prefrontal cortex, basal ganglia, and cerebellum. These brain differences explain why people with ADHD struggle with tasks that others may find automatic, like sustained attention, organization, and impulse control. Understanding ADHD as a neurobiological condition helps reduce blame and stigma while supporting the need for appropriate accommodations and treatment.


    • Executive functioning deficits and their real-world impact: Executive functions are the mental skills that include working memory, flexible thinking, and self-control. ADHD primarily affects these "CEO" functions of the brain. This explains why someone with ADHD might be intelligent and capable but struggle with seemingly simple tasks like remembering instructions, managing time, or organizing materials. These aren't character flaws or laziness but genuine neurological challenges that require specific strategies and sometimes accommodations to overcome.


    • The role of dopamine and motivation: ADHD brains have differences in dopamine pathways, which affect motivation, reward processing, and the ability to sustain attention on less immediately rewarding tasks. This explains why people with ADHD can hyperfocus on interesting activities but struggle with routine or boring tasks. It's not about willpower or caring less; it's about neurochemical differences that make some activities feel unrewarding or even physically uncomfortable to pursue.


    • Medication myths and realities: ADHD medications don't "cure" ADHD but help normalize brain chemistry to improve attention, reduce impulsivity, and enhance executive functioning. Stimulant medications are among the most well-researched and effective treatments in all of medicine, with decades of safety data. They don't change personality or turn children into "zombies" when properly prescribed and monitored. The goal is to help the person access their natural abilities and potential by reducing the neurological barriers that ADHD creates.


    • Strengths and positive aspects of ADHD: While ADHD presents challenges, it also comes with potential strengths including creativity, out-of-the-box thinking, high energy, resilience, hyperfocus abilities, and entrepreneurial thinking. Many successful individuals in various fields have ADHD. Treatment isn't about eliminating all ADHD traits but about managing the problematic aspects while preserving and channeling the positive characteristics. Understanding this helps maintain self-esteem and motivation for treatment.


    • Lifelong nature and changing presentations: ADHD is a lifelong condition, though symptoms and their impact change across development. Hyperactivity often decreases with age while attention and executive functioning challenges may persist or become more apparent as life demands increase. Adult ADHD may look different from childhood ADHD, often presenting as chronic disorganization, procrastination, relationship difficulties, or career underachievement. Recognizing these changing presentations helps with appropriate treatment adjustments throughout life.

    Reference Materials and Further Reading

    Clinical Practice Guidelines

    Emerging Research

    Precision medicine approaches to ADHD treatment

    • Buitelaar J, Bölte S, Brandeis D, Caye A, Christmann N, Cortese S, Coghill D, Faraone SV, Franke B, Gleitz M, Greven CU, Kooij S, Leffa DT, Rommelse N, Newcorn JH, Polanczyk GV, Rohde LA, Simonoff E, Stein M, Vitiello B, Yazgan Y, Roesler M, Doepfner M, Banaschewski T. Toward Precision Medicine in ADHD. Front Behav Neurosci. 2022 Jul 6;16:900981. doi: 10.3389/fnbeh.2022.900981. PMID: 35874653; PMCID: PMC9299434.

    Digital therapeutics and technology-based interventions

    • Kollins SH, DeLoss DJ, Cañadas E, Lutz J, Findling RL, Keefe RSE, Epstein JN, Cutler AJ, Faraone SV. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Health. 2020 Apr;2(4):e168-e178. doi: 10.1016/S2589-7500(20)30017-0. Epub 2020 Feb 24. PMID: 33334505.

    Adult ADHD recognition and treatment

    • Young S, Bramham J, Gray K, Rose E. The experience of receiving a diagnosis and treatment of ADHD in adulthood: a qualitative study of clinically referred patients using interpretative phenomenological analysis. J Atten Disord. 2008 Jan;11(4):493-503. doi: 10.1177/1087054707305172. Epub 2007 Aug 21. PMID: 17712173.

    Neuroplasticity and cognitive training

    • Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, Holtmann M, Santosh P, Stevenson J, Stringaris A, Zuddas A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):164-74. doi: 10.1016/j.jaac.2014.12.010. Epub 2014 Dec 29. Erratum in: J Am Acad Child Adolesc Psychiatry. 2015 May;54(5):433. PMID: 25721181; PMCID: PMC4382075.

    Inflammation and ADHD

    • Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention deficit hyperactivity disorder. Pharmacol Biochem Behav. 2019 Jul;182:22-34. doi: 10.1016/j.pbb.2019.05.005. Epub 2019 May 16. PMID: 31103523; PMCID: PMC6855401.

    Specialized Books for Clinicians

    "Taking Charge of ADHD: The Complete, Authoritative Guide for Parents" by Russell A. Barkley

    • The gold standard resource for understanding ADHD in children and adolescents. Dr. Barkley, a leading ADHD researcher, provides comprehensive coverage of assessment, treatment, and management strategies. Essential for clinicians working with families affected by ADHD.

    "ADHD in Adults: What the Science Says" by Russell A. Barkley, Kevin R. Murphy, and Mariellen Fischer

    • The definitive clinical guide to adult ADHD, covering assessment, diagnosis, and treatment. Provides detailed protocols for evaluating adults and addresses the unique challenges of ADHD across the lifespan.

    “ADHD 2.0: New Science and Essential Strategies for Thriving with Distraction - from Childhood through Adulthood” by Edward M. Hallowell and John J. Ratey

    • A strengths-oriented overview of ADHD featuring insights from cutting-edge research.

    "Attention-Deficit Hyperactivity Disorder: A Clinical Workbook" by Russell A. Barkley and Kevin R. Murphy

    • A comprehensive clinical workbook providing assessment forms, rating scales, and treatment protocols. Includes reproducible materials and step-by-step guidance for clinical practice.

    "Smart but Scattered: The Revolutionary 'Executive Skills' Approach to Helping Kids Reach Their Potential" by Peg Dawson and Richard Guare

    • Focuses on executive functioning deficits in ADHD and provides practical strategies for building these crucial skills in children and adolescents. Excellent resource for clinicians, parents, and educators.

    "The ADHD Effect on Marriage: Understand and Rebuild Your Relationship in Six Steps" by Melissa Orlov

    • Addresses the impact of ADHD on relationships and provides practical strategies for couples. Essential reading for clinicians treating adults with ADHD and relationship difficulties.

    Last Updated: June 2025

    Want to see it for yourself?

    Discover how Allia can transform your operations and patient care.

    Trusted by world’s leading organizations

    Want to see it for yourself?

    Discover how Allia can transform your operations and patient care.

    Trusted by world’s leading organizations